公开(公告)号：US20250012805A1

公开(公告)日：2025-01-09

申请号：US18708619

申请日：2022-11-10

Applicant: INSTITUT GUSTAVE ROUSSY ,  INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITE PARIS-SACLAY

Inventor： LAMBROS TSELIKAS ,  FRANÇOIS-XAVIER DANLOS ,  DELPHINE BREDEL ,  SANDRINE SUSINI ,  MÉLODIE BONVALET ,  SÉVERINE MOURAUD ,  CAROLINE ROBERT ,  AURÉLIEN MARABELLE

IPC: G01N33/574

Abstract: The present invention relates to a method of predicting, assessing or monitoring the sensitivity of a subject having a cancer to an immunotherapy, preferably to an immunotherapy combining at least two immunotherapeutic agents, and to corresponding kits and uses thereof. The method of predicting, assessing or monitoring the sensitivity of a subject having a tumor to an immunotherapy typically comprises a step of assessing, before any immunotherapeutic treatment step in the subject, the presence of CD4+CD25highCD39high T cells in a tumor sample of the subject, the presence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of sensitivity of the subject to the immunotherapy, and the absence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of resistance of the subject to the immunotherapy.

公开(公告)号：US20240301499A1

公开(公告)日：2024-09-12

申请号：US18262102

申请日：2022-01-21

Applicant: Institut Gustave Roussy

Inventor： Nathalie GASPAR ,  Antonin MARCHAIS

IPC: C12Q1/6886 ,  A61K31/4409 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/4409 ,  A61P35/00 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention provides tools for stratifying patients suffering from osteosarcoma, in order to identify patients having poor prognosis tumors. The invention also pertains to the use of an inhibitor of the PPARγ pathway as an antineoplastic treatment to improve the overall survival of patients with a poor prognosis osteosarcoma.

公开(公告)号：US20240093233A1

公开(公告)日：2024-03-21

申请号：US18261051

申请日：2022-01-13

Applicant: VIROXIS ,  INSTITUT PASTEUR ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT GUSTAVE ROUSSY (IGR)

Inventor： Thierry HEIDMANN ,  Frederic TANGY

IPC: C12N15/86 ,  A61P31/18 ,  C07K14/15 ,  C12N7/00

CPC classification number: C12N15/86 ,  A61P31/18 ,  C07K14/15 ,  C12N7/00 ,  C12N2740/16122 ,  C12N2760/18422 ,  C12N2760/18443 ,  C12N2770/24122

Abstract: The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.

公开(公告)号：US20230390312A1

公开(公告)日：2023-12-07

申请号：US17767474

申请日：2020-10-09

Applicant: INSTITUT GUSTAVE ROUSSY

Inventor： ANGELO PACI ,  NATHALIE CHAPUT ,  JEAN-LUC PERFETTINI ,  JULIA DELAHOUSSE

IPC: A61K31/675 ,  A61K45/06 ,  A61P35/00 ,  A61P37/02

CPC classification number: A61K31/675 ,  A61K45/06 ,  A61P35/00 ,  A61P37/02 ,  A61K2039/505

Abstract: The present invention relates to novel therapeutic combinations comprising an oxazaphosphorine derivative and an immune checkpoint modulator for the treatment or the prevention of cancers.

公开(公告)号：US20230302031A1

公开(公告)日：2023-09-28

申请号：US17928352

申请日：2021-06-01

Applicant: Institut Gustave-Roussy

Inventor： Jean-Luc PERFETTINI ,  Deborah LECUYER ,  Desiree TANNOUS ,  Awatef ALLOUCH ,  Oliver DELELIS ,  Frederic SUBRA

IPC: A61K31/7048 ,  A61K45/06 ,  A61P11/00 ,  A61P31/14 ,  A61K31/196 ,  A61K31/64 ,  A61K31/191

CPC classification number: A61K31/7048 ,  A61K45/06 ,  A61P11/00 ,  A61P31/14 ,  A61K31/196 ,  A61K31/64 ,  A61K31/191

Abstract: The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.

公开(公告)号：US20220202904A1

公开(公告)日：2022-06-30

申请号：US17695688

申请日：2022-03-15

Applicant: Cytune Pharma ,  Institut Gustave Roussy (IGR)

Inventor： David Bechard ,  Nathalie Chaput ,  Melanie Desbois

IPC: A61K38/20 ,  C07K16/30 ,  A61K39/395 ,  A61K38/17 ,  C07K14/715 ,  A61K9/00 ,  C07K16/28 ,  C07K14/54

Abstract: The present invention relates to a combined pharmaceutical composition, adapted for simultaneous, separate, or sequential administration for treating cancer in a subject comprising (a) a conjugate comprising (i) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and ii) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15Rα or derivatives thereof; a polynucleotide coding therefore, or a vector comprising such a polynucleotide; and (b) an antibody antagonizing an immune pathway implicated in the inhibition of T cell activation, or a fragment thereof, a polynucleotide coding therefore, or a vector comprising such a polynucleotide.

公开(公告)号：US20220016188A1

公开(公告)日：2022-01-20

申请号：US17296072

申请日：2019-11-21

Applicant: Board of Regents, The University of Texas System ,  Institut Gustave Roussy

Inventor： Jennifer A. WARGO ,  Vancheswaran GOPALAKRISHNAN ,  Miles C. ANDREWS ,  Laurence ZITVOGEL ,  Valerio IEBBA

IPC: A61K35/747 ,  A61K35/741 ,  A61K39/395 ,  A61P35/00 ,  C12Q1/689

Abstract: Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and/or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides fmegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, or B7-2 inhibitor.

公开(公告)号：US10954515B2

公开(公告)日：2021-03-23

申请号：US15568009

申请日：2016-04-21

Applicant: INSTITUT GUSTAVE ROUSSY

Inventor： Iryna Pirozhkova ,  Vasily Ogryzko

IPC: C12N15/113 ,  A61K31/7088 ,  A61P35/00 ,  C07K14/47 ,  A61P21/00 ,  A61P19/00 ,  A61K38/48 ,  C07K16/18 ,  G01N33/50

Abstract: The present invention relates to products and compositions as well as their therapeutic uses in human or veterinary medicine. In particular, the invention provides ZNF555 as a new therapeutic target for the prevention or treatment of a musculoskeletal disease in a subject. Particular embodiments include wherein the musculoskeletal disease is selected from Facioscapulohumeral Dystrophy (FSHD), a myopathy, musculoskeletal fibromatosis and muscular cachexia. Also disclosed is a method for identifying and selecting a compound inhibiting or decreasing the expression or activity of ZNF555, the method comprising a step of detecting and/or measuring the level of expression of ZNF555 or ANTI in a muscle cell in the presence of a test compound, wherein an absent or decreased expression of ZNF555 or ANTI in comparison with a control muscle cell that has not been exposed to or contacted with the test compound, is indicative of the capacity of said compound to inhibit or decrease the expression or activity of ZNF555 in said cell.

公开(公告)号：US10899838B2

公开(公告)日：2021-01-26

申请号：US15316074

申请日：2015-06-05

Applicant: Universite de Lille ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS— ,  INSTITUT GUSTAVE ROUSSY ,  CELLVAX ,  UNIVERSITE PARIS-SUD

Inventor： Nadira Delhem ,  Pierre Busson ,  Olivier Morales ,  Clement Barjon ,  Dhafer Mrizak ,  Claire Lhuillier ,  Rami Mustapha

IPC: A61K39/385 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/18 ,  A61K39/395 ,  A61K45/06

Abstract: The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.

公开(公告)号：US20200376052A1

公开(公告)日：2020-12-03

申请号：US16985607

申请日：2020-08-05

Applicant: Institut Gustave-Roussy ,  Transgene SA

Inventor： Laurence Zitvogel ,  Xavier Preville ,  Laetitia Fend

IPC: A61K35/768 ,  A61K9/00 ,  A61K35/28 ,  A61K38/19 ,  A61K39/395 ,  C07K16/28 ,  C12N5/00 ,  C12N7/00

Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).